AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34269848 — intervention group
Group type: EXPERIMENTAL
Intervention: MB02
Number of subjects: 48
Study 34269848 — intervention group
Group type: COMPARATOR
Intervention: Reference bevacizumab
Number of subjects: 48
Study 35526047 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 0
Study 35526047 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex
Number of subjects: 0
Study 33601928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 70
Study 33601928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32921196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (biannual counseling based on Nordic Nutrition Recommendations)
Number of subjects: 877
Study 32921196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (including dietary cholesterol as an additional target)
Number of subjects: 877
Study 35405955 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin combined with evening primrose oil (4 × 510 mg/day)
Number of subjects: 50
Study 35405955 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin
Number of subjects: 50
Study 32771276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks and PLD 40 mg/m2 IV every 4 weeks
Number of subjects: 26
Study 32771276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and PLD combination therapy
Number of subjects: 26
Study 32771276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 26
Study 35361328 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB238
Number of subjects: 99
Study 35361328 — intervention group
Group type: COMPARATOR
Intervention: EU-bevacizumab
Number of subjects: 99
Study 35361328 — intervention group
Group type: COMPARATOR
Intervention: US-bevacizumab
Number of subjects: 99
Study 35361328 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (FKB238, EU-bevacizumab, US-bevacizumab)
Number of subjects: 99
Study 33761573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion (HMP)
Number of subjects: 0
Study 33761573 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 0
Study 32159313 — intervention group
Group type: COMPARATOR
Intervention: 5 Hz rTMS
Number of subjects: 41
Study 32159313 — intervention group
Group type: COMPARATOR
Intervention: iTBS
Number of subjects: 41
Study 32159313 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS and iTBS
Number of subjects: 41
Study 35398854 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face motivational interviewing (MI)
Number of subjects: 150
Study 35398854 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call motivational interviewing (MI)
Number of subjects: 150
Study 35398854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 32930336 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week adaptive gamified Go/NoGo inhibitory control training (ICT)
Number of subjects: 0
Study 32930336 — intervention group
Group type: COMPARATOR
Intervention: 2-back working-memory training
Number of subjects: 0
Study 32469906 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention using video, poster, and leaflet
Number of subjects: 452
Study 32469906 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention using leaflets
Number of subjects: 452
Study 35880650 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP-MST
Number of subjects: 52
Study 35880650 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP
Number of subjects: 52
Study 35880650 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study 33838478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-field gel electrophoresis (PFGE)
Number of subjects: 200
Study 33838478 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome analysis
Number of subjects: 200
Study 33838478 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilocus sequence typing (MLST)
Number of subjects: 200
Study 33838478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rarefaction analysis
Number of subjects: 200
Study 33729323 — intervention group
Group type: EXPERIMENTAL
Intervention: Chahuang ointment
Number of subjects: 171
Study 33729323 — intervention group
Group type: COMPARATOR
Intervention: Mucopolysaccharide Polysulfate cream
Number of subjects: 171
Study 33729323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study 33303446 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐MIST plus Bio‐Oss Collagen
Number of subjects: 40
Study 33303446 — intervention group
Group type: COMPARATOR
Intervention: M‐MIST
Number of subjects: 40
Study 33803073 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel multicomponent (MLMC) intervention
Number of subjects: 0
Study 33803073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-components of the MLMC intervention
Number of subjects: 0
Study 33161472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen formulations with nanostructured lipid carriers (NLCs) containing quercetin
Number of subjects: 60
Study 33161472 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen formulations without antioxidants
Number of subjects: 60
Study 33161472 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen formulations with antioxidants in free form
Number of subjects: 60
Study 33161472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen formulations with antioxidants loaded in NLCs
Number of subjects: 60
Study 34197060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic transcranial direct current stimulation plus resistance training (a‐tDCS + RT)
Number of subjects: 28
Study 34197060 — intervention group
Group type: COMPARATOR
Intervention: Sham plus resistance training (Sham + RT)
Number of subjects: 28
Study 32452208 — intervention group
Group type: EXPERIMENTAL
Intervention: HGH treatment
Number of subjects: 19
Study 32452208 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 33170109 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (N=7,782)
Number of subjects: 15762
Study 33170109 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (N=7,981)
Number of subjects: 15762
Study 33334577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile dermoscopy-enhanced self-skin examination
Number of subjects: 234
Study 33334577 — intervention group
Group type: COMPARATOR
Intervention: Naked-eye skin self-examination
Number of subjects: 234
Study 33334577 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic concordance
Number of subjects: 234
Study 34089371 — intervention group
Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 89
Study 34089371 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult joggers/runners
Number of subjects: 89
Study 32496921 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 546
Study 32496921 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 546
Study 32496921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 546
Study 33000891 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term injectable opioid agonist treatment with diacetylmorphine (DAM)
Number of subjects: 22
Study 36456622 — intervention group
Group type: COMPARATOR
Intervention: tDCS (transcranial direct current stimulation) combined with cognitive training
Number of subjects: 25
Study 36456622 — intervention group
Group type: EXPERIMENTAL
Intervention: rs-dFC state 4
Number of subjects: 25
Study 36456622 — intervention group
Group type: COMPARATOR
Intervention: rs-sFC measure
Number of subjects: 25
Study 34570203 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial aftercare (PAC) program
Number of subjects: 419
Study 34570203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 419
Study 33153350 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO) in patient group (PG)
Number of subjects: 60
Study 33153350 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) in patient group (PG)
Number of subjects: 60
Study 33153350 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO) in patient group (PG) with greater levels of kinesiophobia
Number of subjects: 60
Study 33153350 — intervention group
Group type: COMPARATOR
Intervention: Action Observation (AO) in control group (CG)
Number of subjects: 60
Study 33153350 — intervention group
Group type: COMPARATOR
Intervention: Motor Imagery (MI) in control group (CG)
Number of subjects: 60
Study 32723393 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 92
Study 32723393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 36494644 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-arm multi-stage design
Number of subjects: 0
Study 36494644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian response adaptive randomization design
Number of subjects: 0
Study 36494644 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive phase IIc designs
Number of subjects: 0
Study 36494644 — intervention group
Group type: EXPERIMENTAL
Intervention: Seamless designs
Number of subjects: 0
Study 33764619 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-8998 (10 mg twice daily)
Number of subjects: 83
Study 33764619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 33105261 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive speech intelligibility task using Modified Rhyme Test in noisy environments.
Number of subjects: 174
Study 33105261 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of signal-to-noise ratio (SNR) during speech intelligibility task.
Number of subjects: 174
Study 35365958 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of low-dose methotrexate (12.5 mg divided in 5 days/week)
Number of subjects: 0
Study 35365958 — intervention group
Group type: COMPARATOR
Intervention: Weekly administration of low-dose methotrexate (12.5 mg once per week)
Number of subjects: 0
Study 35365958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both daily and weekly administration of low-dose methotrexate
Number of subjects: 0
Study 35365958 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and weekly administration of low-dose methotrexate
Number of subjects: 0
Study 34132789 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of RA
Number of subjects: 0
Study 34132789 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined RA
Number of subjects: 0
Study 34132789 — intervention group
Group type: EXPERIMENTAL
Intervention: RA in Asian population
Number of subjects: 0
Study 34132789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies against citrullinated proteins-positive RA
Number of subjects: 0
Study 32515134 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Watch (WW)
Number of subjects: 42
Study 32515134 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (WW and PW)
Number of subjects: 42
Study 616038469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 35
Study 616038469 — intervention group
Group type: COMPARATOR
Intervention: Topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab
Number of subjects: 35
Study 616038469 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide bid for 4 weeks
Number of subjects: 35
Study 36164983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) 1350 mg
Number of subjects: 22
Study 36164983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34162644 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 10 cmH2O
Number of subjects: 200
Study 34162644 — intervention group
Group type: COMPARATOR
Intervention: CPAP 7 cmH2O
Number of subjects: 200
Study 32701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17-beta-estradiol 0.5 mg/d
Number of subjects: 1005
Study 32701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 to 20 mg/d
Number of subjects: 1005
Study 32701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 1005
Study 32701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga/Aerobic exercise
Number of subjects: 1005
Study 32701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg/d
Number of subjects: 1005
Study 32701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 1.8 g/d
Number of subjects: 1005
Study 32701665 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1005
Study 35121216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (0.5 mg) every 3 months for 24 months
Number of subjects: 108
Study 35121216 — intervention group
Group type: COMPARATOR
Intervention: Sham injection every 3 months for 24 months
Number of subjects: 108
Study 34278942 — intervention group
Group type: EXPERIMENTAL
Intervention: biofeedback at high stroke rates (BFb90)
Number of subjects: 30
Study 34278942 — intervention group
Group type: EXPERIMENTAL
Intervention: biofeedback at low stroke rates (BFb60)
Number of subjects: 30
Study 34278942 — intervention group
Group type: COMPARATOR
Intervention: control at high stroke rates
Number of subjects: 30
Study 34278942 — intervention group
Group type: COMPARATOR
Intervention: control at low stroke rates
Number of subjects: 30
Study 33033047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor administered IV periprocedurally
Number of subjects: 38
Study 34520130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (6 weeks)
Number of subjects: 31
Study 34520130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators + inhaled corticosteroids (ICS) (12 weeks)
Number of subjects: 31
Study 34520130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators + ICS
Number of subjects: 31
Study 33129298 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 64
Study 36405425 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 61
Study 36405425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based risk estimates provided to neurosurgeons for treatment recommendations.
Number of subjects: 139
Study 32119677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no evidence-based risk estimates provided).
Number of subjects: 139
Study 32119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based risk estimates provided to neurosurgeons for prognostic beliefs.
Number of subjects: 139
Study 36026559 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet lysate (PL) - sub acromial injections every week for a total of 3 injections
Number of subjects: 40
Study 36026559 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine - two injections once every two weeks
Number of subjects: 40
Study 32851660 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically raised LDL cholesterol levels
Number of subjects: 121885
Study 32851660 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted HDL cholesterol levels
Number of subjects: 121885
Study 32851660 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted increased LDL cholesterol levels
Number of subjects: 121885
Study 32851660 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 121885
Study 35049407 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft cushioning shoes
Number of subjects: 848
Study 35049407 — intervention group
Group type: COMPARATOR
Intervention: Hard cushioning shoes
Number of subjects: 848
Study 35049407 — intervention group
Group type: EXPERIMENTAL
Intervention: General running biomechanics
Number of subjects: 848
Study 34515977 — intervention group
Group type: EXPERIMENTAL
Intervention: Envarsus (LCPT)
Number of subjects: 69
Study 34515977 — intervention group
Group type: COMPARATOR
Intervention: Standard body weight-based approach
Number of subjects: 69
Study 36324156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desk (SSD) intervention
Number of subjects: 0
Study 34570004 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training, four-session telephone follow-up, and one text message weekly
Number of subjects: 64
Study 34570004 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 64
Study 33205347 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating Matters®: Strategies to Promote Healthy Teen Relationships
Number of subjects: 0
Study 33205347 — intervention group
Group type: COMPARATOR
Intervention: Another evidence‐based program
Number of subjects: 0
Study 32070419 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental cleaning bundle intervention
Number of subjects: 11
Study 32070419 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 11
Study 35008009 — intervention group
Group type: COMPARATOR
Intervention: Serum BAFF levels in CRSwNP patients
Number of subjects: 120
Study 35008009 — intervention group
Group type: COMPARATOR
Intervention: Serum BAFF levels in recurrence group
Number of subjects: 120
Study 35008009 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BAFF as a predictive biomarker
Number of subjects: 120
Study 34014922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (F = 100 Hz, pulse duration = 200 μs, for 30 min)
Number of subjects: 174
Study 34014922 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (same parameters as active TENS, but for only 30 s, then ramped off over 15 s)
Number of subjects: 174
Study 34014922 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet (instructions about health promotion and education actions related to PD)
Number of subjects: 174
Study 33007981 — intervention group
Group type: EXPERIMENTAL
Intervention: JRE + dark chocolate supplementation (JD)
Number of subjects: 48
Study 33007981 — intervention group
Group type: EXPERIMENTAL
Intervention: JRE + white chocolate (JW)
Number of subjects: 48
Study 33007981 — intervention group
Group type: EXPERIMENTAL
Intervention: dark chocolate supplementation (DS)
Number of subjects: 48
Study 33007981 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study 34105104 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia only
Number of subjects: 253
Study 34105104 — intervention group
Group type: COMPARATOR
Intervention: OSA only
Number of subjects: 253
Study 34143642 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of critical care nutrition
Number of subjects: 0
Study 32883309 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate programmed cryotherapy and continuous passive motion (CPM) applied within 1 hour after surgery.
Number of subjects: 60
Study 32883309 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryotherapy or CPM).
Number of subjects: 60
Study 35468803 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI group (goal-directed analgesia targeting 50-80 ANI range with prophylactic morphine if ANI < 50)
Number of subjects: 0
Study 35468803 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 0
Study 35468803 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI group (goal-directed analgesia)
Number of subjects: 0
Study 33465098 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated screening (ITS)
Number of subjects: 2
Study 33465098 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of ITS)
Number of subjects: 2
Study 34755655 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA, 1.6 g/day)
Number of subjects: 163
Study 34755655 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA, 0.7 g/day)
Number of subjects: 163
Study 34755655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 34279598 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 35
Study 34279598 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 35
Study 33106976 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based supportive communication (CSC) intervention
Number of subjects: 20
Study 33106976 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 20
Study 32453304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session of plyometric training (1SPT)
Number of subjects: 30
Study 32453304 — intervention group
Group type: COMPARATOR
Intervention: 2 sessions of plyometric training (2SPT)
Number of subjects: 30
Study 32453304 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (PT)
Number of subjects: 30
Study 33277203 — intervention group
Group type: EXPERIMENTAL
Intervention: Music medicine
Number of subjects: 150
Study 33277203 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin contact with the newborn
Number of subjects: 150
Study 33277203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 150
Study 32109257 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptable implementation package targeting risky prescribing
Number of subjects: 144
Study 32109257 — intervention group
Group type: COMPARATOR
Intervention: Adaptable implementation package targeting diabetes control
Number of subjects: 144
Study 32109257 — intervention group
Group type: COMPARATOR
Intervention: Adaptable implementation package targeting blood pressure control
Number of subjects: 144
Study 32109257 — intervention group
Group type: COMPARATOR
Intervention: Adaptable implementation package targeting anticoagulation prescribing
Number of subjects: 144
Study 32109257 — intervention group
Group type: COMPARATOR
Intervention: Adaptable implementation package targeting co-prescription of aspirin and clopidogrel without gastro-protection
Number of subjects: 144
Study 33177324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone administration by parents with high anxiety
Number of subjects: 173
Study 33177324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone administration by parents with high stress
Number of subjects: 173